Process2Clean®: Process Cleaning Detergents

Article

Sponsored Content

VAI’s Process2Clean®, Process Cleaning Detergents, are designed to remove process residues that could contaminate or adulterate further product manufacturing in the pharmaceutical, biotechnology, medical device, and research & development industries.

VAI’s GMP Process2Clean (P2C) cleaning products are specifically formulated for critical process cleaning applications. Each detergent is engineered to effectively remove numerous product residues found in pharmaceutical, biotechnology, medical device, and research & development industries. Process2Clean detergents successfully remove existent residues present in process manufacturing and reduce them down to acceptable trace residual limits. This critical process assures that product contact surfaces are clean prior to subsequent manufacturing and eliminates the possibility of product contamination or product adulteration.

 

Process2Clean detergents include an Alkaline Detergent, an Acid Based Detergent, a Hydroxyacetic Acid Cleaner, a General Purpose Cleaning Detergent, a Neutral pH Cleaning Additive, and a Chlorinated Alkaline Cleaning Detergent. This complete line of Process2Clean detergents are capable of removing a wide range of residues from inorganic to organic process soils and can be used in numerous cleaning systems from automated to manual.

 

Process2Clean detergents are formulated with Water for Injection (WFI) and are highly concentrated which translates into low cost per use. All shipments of Process2Clean are delivered with lot specific documentation and are completely validated with an extensive validation support package available. Process2Clean Detergents are available in 1, 5, 30, 55, and 275 gallon options either sterile or non-sterile.

 

Contact Details:

Company name: Veltek Associates, Inc.
Website: www.sterile.com
E-mail: moira.omalley@sterile.com

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content